Company Details
Aquinox Pharmaceuticals
450-887 Great Northern Way, Suite 450, Vancouver, British Columbia, V5T 4T5, Canada
Overview
Aquinox Pharmaceuticals, based in Vancouver, BC, Canada, develops small‑molecule therapeutics targeting inflammatory disease and cancer. The company closed a US$25M Series B financing to advance its programs. Proceeds will move its lead SH2‑containing inositol‑5′‑phosphatase (SHIP1) agonist candidate, AQX‑1125, into Phase I and Phase II clinical studies. Aquinox will also continue drug discovery to nominate a second clinical candidate and additional pipeline candidates from its SHIP1 program. The company’s work centers on its SHIP1 agonist platform and clinical development of AQX‑1125.
- Total raised
- $25M
- Funding rounds
- 1
- Latest round
- Series B
- Latest activity
- Jun 2010
Industries
- Biotechnology
- Health Care
- Therapeutics
Recent funding
Series B
Jun 2010
$25M
Team
No current team members are available.